Table 3.

Multivariable Analysis for Association Between Neuropathy and Survival Outcomes Using a Cox Time-Varying Model

Tumor Subtype	No. of Patients	Phenotype	No. of Events	HR	95% CI	P
All types	4,478	OS	812	0.96	0.79 to 1.16	.66
		DFS	1134	1.01	0.86 to 1.18	.90
		RFS	1082	1.01	0.86 to 1.19	.89
HER2 positive	900	OS	177	0.80	0.51 to 1.26	.33
		DFS	244	0.77	0.52 to 1.14	.19
		RFS	230	0.83	0.56 to 1.23	.35
TNBC	829	OS	219	1.31	0.95 to 1.81	.10
		DFS	270	1.19	0.89 to 1.61	.24
		RFS	255	1.17	0.86 to 1.59	.32
ER positive/HER2 negative	2,614	OS	384	0.78	0.58 to 1.05	.10
		DFS	581	0.97	0.78 to 1.22	.81
		RFS	558	0.96	0.77 to 1.21	.75

NOTE: Adjusted covariates included age (≤ 45, 46-65, and > 65 years), race (black v others), obesity (body mass index ≥ 30 kg/m² v others), menopausal status (premenopausal v postmenopausal), hyperglycemia (yes v no), tumor size (> 2 v ≤ 2 cm), nodal status (0, 1-3 and > 3), and treatment arm (every 3-week paclitaxel, weekly paclitaxel, every 3-week docetaxel, and weekly docetaxel arms). There were 76 patients with missing values for body mass index (29 patients) and/or node status (23 patients) and/or tumor size (42 patients), and 4,478 patients were included in the multivariable Cox regression for all patients. Among the 4,478 patients, 430 patients had missing values for HER2 status, 25 patients had missing ER status, and 42 patients had missing progesterone receptor status. P was compared with P < .05/3 = .017 for the significance test for the three subgroup analyses.

Abbreviations: DFS, disease-free survival; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; OS, overall survival; RFS, recurrence-free survival; TNBC, triple-negative breast cancer.